Fifty 1 Labs, Inc. to Host Virtual Shareholder Teleconference Featuring World-Class Leadership Team, including Dr. James Orbinski, who received the Nobel Peace Prize on Behalf of Médecins Sans Frontières

Core Insights - Fifty 1 Labs, Inc. is hosting a virtual shareholder teleconference featuring Dr. James Orbinski, emphasizing the company's commitment to global health innovation through AI-powered solutions [1][2] Company Overview - Fifty 1 Labs, Inc. focuses on AI-driven innovations in functional medicine and wellness, leveraging its subsidiary Fifty 1 AI Labs to repurpose drugs and develop personalized health solutions [11] Strategic Roadmap - The company's strategic plan includes three pillars: (1) $1 million investment in R&D for AI therapies, (2) a targeted $5–10 million biotech acquisition by July 2027, and (3) uplisting to OTCQB by Q1 2026 and NASDAQ thereafter [3][4] Leadership Team - The leadership team includes experienced professionals such as CEO Paul Arora, Dr. James Orbinski as Senior Scientist, and other experts in biotech and AI, showcasing a strong commitment to the company's vision [5][6] Innovation and Market Positioning - Fifty 1 AI Labs emphasizes off-patent drug repurposing using real-world clinical data, aiming for faster and more affordable therapies, and has established partnerships with leading universities for evidence-based supplements [6][7] Shareholder Engagement - The teleconference will allow shareholders to engage with the leadership team, who will address forward-looking strategies and invite questions for future discussions [8][9]